Why Did United Therapeutics Plunge 12.89%?
On June 10, 2025, United TherapeuticsUTHR-- experienced a significant drop of 12.89% in pre-market trading, sparking concerns among investors about the company's future prospects.
JPMorgan Chase & Co. recently adjusted their outlook on United Therapeutics,UTHR-- lowering their price target from $355.00 to $350.00 while maintaining an "overweight" rating. This revision reflects the bank's updated analysis of the company's financial performance and market position.
Two Sigma Investments LP has also made notable moves, acquiring 52 shares of United Therapeutics. This investment signals confidence in the company's long-term growth potential, despite recent market volatility.
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
Comments
No comments yet